Pharmacological therapy of tachyarrhythmias during pregnancy

16Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

Abstract

Tachyarrhythmias are the most frequently observed cardiac complications during pregnancy. The majority of these maternal and foetal arrhythmias are supraventricular tachyarrhythmias; ventricular tachyarrhythmias are rare. The use of anti-arrhythmic drugs (AADs) during pregnancy is challenging due to potential foetal teratogenic effects. Maintaining stable and effective therapeutic maternal drug levels is difficult due to haemodynamic and metabolic alterations. Pharmacological treatment of tachyarrhythmias is indicated in case of maternal haemodynamic instability or hydrops fetalis. Evidenc e regarding the efficacy and safety of AAD therapy during pregnancy is scarce and the choice of AAD should be based on individual risk assessments for both mother and foetus. This review outlines the current knowledge on the development of tachyarrhythmias during pregnancy, the indications for and considerations of pharmacological treatment and its potential side-effects.

Cite

CITATION STYLE

APA

Yaksh, A., Van Lisette Der Does, J. M. E., Lanters, E. A. H., & De Groot, N. M. S. (2016). Pharmacological therapy of tachyarrhythmias during pregnancy. Arrhythmia and Electrophysiology Review, 5(1), 41–44. https://doi.org/10.15420/AER.2016.1.2

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free